METHOD FOR THE TREATMENT OR PREVENTION OF CHOLESTEROL-RELATED DISEASES

DE602012082148T2Active Publication Date: 2026-07-15AMGEN INC

Patent Information

Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
AMGEN INC
Filing Date
2012-05-10
Publication Date
2026-07-15

AI Technical Summary

Technical Problem

Current treatments for cholesterol-related disorders, such as hypercholesterolemia and heart disease, are inadequate for some patients, and there is a need for more aggressive therapies to lower LDL-C levels effectively, especially for those intolerant to or not responding to statin therapy.

Method used

Development of a monoclonal antibody specifically targeting PCSK9, administered at varying doses and schedules, to reduce serum LDL cholesterol levels by at least 15-90% in patients, potentially combined with other cholesterol-lowering agents.

Benefits of technology

The antibody effectively lowers LDL cholesterol levels by 15-90% in patients, providing a therapeutic option for those not responding to statins and addressing the need for more aggressive treatment of cholesterol-related disorders.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.